Geron Corporation (GERN) has unveiled a strategic restructuring initiative aimed at fostering long-term value for its patients and shareholders while enhancing financial discipline. CEO Harout Semerjian highlighted the efforts to streamline the company's organizational structure for strategic advancement and prudent fiscal management.
The company's primary objectives remain focused on expanding the commercial reach of RYTELO in the U.S., seeking opportunities to extend its availability internationally, and progressing the Phase 3 IMpactMF trial. This restructuring is anticipated to significantly impact 2026 operating expenses, positioning Geron effectively to address patient needs.
A key component of Geron's strategy includes a one-third reduction in its workforce, which currently stands at approximately 260 employees. The restructuring plan is expected to be largely completed by the start of 2026. Consequently, full-year operating expenses for 2026 are projected to be lower than those of 2025, with anticipated savings starting in the first quarter of 2026.
Geron will incur cash-based restructuring charges and will provide further details in a forthcoming Current Report on Form 8-K, to be filed with the SEC.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.